VIVEbiotech is also collaborating with a range of different suppliers to make its operations as efficient as possible.

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of ...

In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Chad Stevens traveled from Idaho to Omaha's Nebraska Medical Center, where he became the hospital's first patient to receive ...

A new study published in the peer-reviewed journal Human Gene Therapy involved the generation of a human monoclonal antibody ...